Successful translational awards

Examples of recently awarded projects and information on why they were funded

Developing a novel compound that improves outcome in sepsis - Dr James Leiper, Medical Research Council

The Translational Award funded two activities:

"Informal interaction between the BHF, applicants and experts in translating academic research is a really good way to progress these awards."
  • Medicinal chemistry, outsourced to a contract research organisation (CRO).
  • Engagement with the FDA, using an experienced regulatory consultant, in a pre-Investigational New Drug (IND) meeting to clarify regulatory requirements.

Application strengths:

  • Addresses an unmet medical need for a disease where there have been many drug failures and no new drugs that improve outcome.
  • Human genetic studies and pre-clinical in vivo data to support target validation.

How the BHF helped:

  • The Translational Awards Committee identified uncertainty relating to regulatory requirements as a concern for investors. They added in this milestone and suggested a regulatory consultant that could help the PI engage with the FDA.

 

A novel transcatheter valve for younger patients with aortic stenosis - Dr Geoff Moggridge, University of Cambridge

 

The Translational Award funded three activities:

  • Ex vivo device design, evaluation and optimisation.
  • In vivo evaluation of delivery technique.
  • In vivo evaluation of endothelial growth, thrombus formation and late removal capacity.

Application strengths:

  • Addresses an unmet medical need that builds on the validated TAVR concept.

  • Strong collaboration with international expert in animal trials.

  • Robust pilot data and initial prototype.

  • Clear vision of the final product and an assessment of barriers that need to be overcome to get to this end goal.

How the BHF helped:

  • Committee highlighted the major risk was whether the device can be removed after a long period of implantation, so suggested increasing the length of the in vivo studies.

 

A diagnostic and prognostic biomarker with improved sensitivity for acute myocardial infarction - Professor Michael Marber, King's College London

The Translational Award funded two activities:

“The award provided the key and timely support needed to bring the necessary academic and commercial partners together to perform a single focussed study." 
  • Creation of standardised kits for assay determination, outsourced to a CRO.
  • Data analysis of biomarker concentration for diagnostic/prognostic performance compared to current troponin diagnostic tests.

Application strengths:

  • Patient and pre-clinical in vivo data to support target validation.
  • PI had talked to investors and diagnostic companies to identify what data they would require before considering investing in or acquiring the technology.